Association between maternal folic acid and/or multivitamin supplementation time and fetal congenital heart disease: based on the China birth cohort study.

IF 3.2 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Jingjing Wang, Simin Zhang, Lijuan Sun, Li Wang, Qingqing Wu
{"title":"Association between maternal folic acid and/or multivitamin supplementation time and fetal congenital heart disease: based on the China birth cohort study.","authors":"Jingjing Wang, Simin Zhang, Lijuan Sun, Li Wang, Qingqing Wu","doi":"10.7150/ijms.102843","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> A multitude of studies have presented inconsistent outcomes regarding the association between maternal folic acid (FA) and/or multivitamin (MV) supplementation and congenital heart disease (CHD) in offspring. This study aimed to estimate supplementation time and CHD based on a prospective China birth cohort study (CBCS). <b>Methods:</b> In the CBCS, 114,670 singleton pregnant women who had pregnancy outcomes until August 2021 and responded to the early pregnancy questionnaire were recruited. The participants were divided into three groups: no FA or MV supplementation, supplementation commencing before pregnancy, and supplementation commencing from early pregnancy. Unadjusted and adjusted logistic regression analyses were employed to calculate the odds ratio (OR) to estimate the relative risk (RR) value of CHD exposure to FA and/or MV. Additionally, the results of this study were combined with previous studies to calculate the pooled RR. Finally, stratification and sensitivity analyses, including the propensity score matching method, were conducted to identify the robustness of the association. <b>Results:</b> Compared with the non-supplemented group, the RRs of CHD in groups with FA and/or MV supplementation, with supplementation before pregnancy, and with supplementation from early pregnancy were 1.23 (95% confidence interval [CI]: 0.76-2.00), 1.30 (95% CI: 0.80-2.13) and 1.19 (95% CI: 0.73-1.93), all demonstrating no statistically significant difference. The pooled RR from the forest plot was 0.98 (95% CI: 0.95-1.01), which is consistent with the findings of this study. Furthermore, the results remained approximately the same in the stratification or sensitivity analyses in different datasets, including performing 1:1 or 1:2 propensity score matching. <b>Conclusions:</b> The present study suggests that FA or MV supplementation before or during early pregnancy may not influence the risk of offspring developing CHD.</p>","PeriodicalId":14031,"journal":{"name":"International Journal of Medical Sciences","volume":"22 2","pages":"260-268"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704702/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/ijms.102843","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A multitude of studies have presented inconsistent outcomes regarding the association between maternal folic acid (FA) and/or multivitamin (MV) supplementation and congenital heart disease (CHD) in offspring. This study aimed to estimate supplementation time and CHD based on a prospective China birth cohort study (CBCS). Methods: In the CBCS, 114,670 singleton pregnant women who had pregnancy outcomes until August 2021 and responded to the early pregnancy questionnaire were recruited. The participants were divided into three groups: no FA or MV supplementation, supplementation commencing before pregnancy, and supplementation commencing from early pregnancy. Unadjusted and adjusted logistic regression analyses were employed to calculate the odds ratio (OR) to estimate the relative risk (RR) value of CHD exposure to FA and/or MV. Additionally, the results of this study were combined with previous studies to calculate the pooled RR. Finally, stratification and sensitivity analyses, including the propensity score matching method, were conducted to identify the robustness of the association. Results: Compared with the non-supplemented group, the RRs of CHD in groups with FA and/or MV supplementation, with supplementation before pregnancy, and with supplementation from early pregnancy were 1.23 (95% confidence interval [CI]: 0.76-2.00), 1.30 (95% CI: 0.80-2.13) and 1.19 (95% CI: 0.73-1.93), all demonstrating no statistically significant difference. The pooled RR from the forest plot was 0.98 (95% CI: 0.95-1.01), which is consistent with the findings of this study. Furthermore, the results remained approximately the same in the stratification or sensitivity analyses in different datasets, including performing 1:1 or 1:2 propensity score matching. Conclusions: The present study suggests that FA or MV supplementation before or during early pregnancy may not influence the risk of offspring developing CHD.

母亲叶酸和/或多种维生素补充时间与胎儿先天性心脏病的关系:基于中国出生队列研究
背景:关于母体叶酸(FA)和/或复合维生素(MV)补充与后代先天性心脏病(CHD)之间的关系,大量研究得出了不一致的结果。本研究旨在基于一项前瞻性中国出生队列研究(CBCS)估计补充时间与冠心病的关系。方法:在CBCS中,招募了114,670名截至2021年8月有妊娠结局的单胎孕妇,并回答了早期妊娠问卷。参与者被分为三组:不补充FA或MV,在怀孕前开始补充,以及从怀孕早期开始补充。采用未调整和调整的logistic回归分析计算比值比(OR),以估计冠心病暴露于FA和/或MV的相对危险度(RR)值。并将本研究结果与前人研究结果相结合,计算合并RR。最后,进行分层和敏感性分析,包括倾向评分匹配方法,以确定关联的稳健性。结果:与未补充组相比,补充FA和/或MV组、孕前补充组和妊娠早期补充组冠心病的rr分别为1.23(95%可信区间[CI]: 0.76-2.00)、1.30 (95% CI: 0.80-2.13)和1.19 (95% CI: 0.73-1.93),差异均无统计学意义。森林样地的合并RR为0.98 (95% CI: 0.95-1.01),与本研究结果一致。此外,在不同数据集的分层或敏感性分析中,包括进行1:1或1:2倾向评分匹配,结果大致相同。结论:目前的研究表明,在怀孕前或怀孕早期补充FA或MV可能不会影响后代患冠心病的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Medical Sciences
International Journal of Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
7.20
自引率
0.00%
发文量
185
审稿时长
2.7 months
期刊介绍: Original research papers, reviews, and short research communications in any medical related area can be submitted to the Journal on the understanding that the work has not been published previously in whole or part and is not under consideration for publication elsewhere. Manuscripts in basic science and clinical medicine are both considered. There is no restriction on the length of research papers and reviews, although authors are encouraged to be concise. Short research communication is limited to be under 2500 words.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信